Innovative use of topical metronidazole

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 525-534

  Zip, Catherine M ^a  

^a Dermatology Centre   (Canada)

Author keywords

Innovative use; Off label use; Rosacea; Topical metronidazole

Indexed keywords

ANTIHISTAMINIC AGENT; AZELAIC ACID; CETUXIMAB; CORTICOSTEROID; DOXYCYCLINE; DOXYCYCLINE FOSFATEX; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; GEFITINIB; HYDROCORTISONE; LAPATINIB; METRONIDAZOLE; MINOCYCLINE; PANITUMUMAB; PIMECROLIMUS; PLACEBO; SULFACETAMIDE; TETRACYCLINE;

ACNE; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADNEXA DISEASE; ANTIBACTERIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE DRYNESS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMEDO; DECUBITUS; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EPITHELIUM TUMOR; EXPERIMENTAL THERAPY; EYEBROW; EYELASH; FIXED DRUG ERUPTION; HAIR GROWTH; HAIR LOSS; HEAD AND NECK CANCER; HUMAN; HYPERPIGMENTATION; LEG ULCER; LUNG NON SMALL CELL CANCER; OFF LABEL DRUG USE; PANCREAS CANCER; PAPULAR RASH; PAPULE; PARONYCHIA; PATCH TEST; PERIORAL DERMATITIS; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; PUSTULE; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ALLERGY; SKIN DISCOMFORT; SKIN TOXICITY; TELANGIECTASIA; TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; VAGINITIS; WOUND; XEROSIS;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; DERMATITIS, PERIORAL; DERMATITIS, SEBORRHEIC; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; METRONIDAZOLE; MULTICENTER STUDIES AS TOPIC; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROSACEA; THERAPIES, INVESTIGATIONAL; WOUNDS AND INJURIES;

EID: 77953244917     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.015     Document Type: Review

References (66)

1. Persi A., Rebora A. Metronidazole and demodex folliculorum. Acta Derm Venereol 1981, 61(2):182-183.
2. Eriksson G., Nord C.E. Impact of topical metronidazole on the skin and colon microflora in patients with rosacea. Infection 1987, 15(1):8-10.
3. Schmadel L.K., McEvoy G.K. Topical metronidazole: a new therapy for rosacea. Clin Pharm 1990, 9(2):94-101.
4. Narayanan S., Hunerbein A., Getie M., et al. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol 2007, 59(8):1125-1130.
5. Neilsen P.G. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol 1983, 108(3):327-332.
6. Aronson I.K., Rumsfield J.A., West D.P., et al. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm 1987, 21(4):346-351.
7. Bleicher P.A., Charles J.H., Sober A.J. Topical metronidazole therapy for rosacea. Arch Dermatol 1987, 123(5):609-614.
8. Breneman D.L., Stewart D., Hevia O., et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998, 61(1):44-47.
9. Nally J.B., Berson D.S. Topical therapies for rosacea. J Drugs Dermatol 2006, 5(1):23-26.
10. Madsen J.T., Thormann J., Kerre S., et al. Allergic contact dermatitis to topical metronidazole-3 cases. Contact Dermatitis 2007, 56(6):364-366.
11. Kirkland C.R., Yelverton C.B., Fleischer A.B., et al. Gel vehicles are not inherently more irritating than creams. J Drugs Dermatol 2006, 5(3):269-272.
12. Dow G., Basu S. A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HAS-3). Cutis 2006, 77():18-26.
13. Yoo J., Reid D.C., Kimball A.B. Metronidazole in the treatment of rosacea: do formulation, dosing and concentration matter?. J Drugs Dermatol 2006, 5(4):317-319.
14. Lamp K.C., Freeman C.D., Klutman N.E., et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999, 36(5):353-373.
15. Jorizzo J.L., Lebwohl M., Tobey R.E. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol 1998, 39(3):502-504.
16. Elewski B.E., Fleischer A.B., Pariser D.M. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003, 139(11):1444-1450.
17. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999, 40():961-965.
18. Wolf J.E., Kerrouche N., Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006, 77(4 ):3-11.
19. Colon L.E., Johnson L.A., Gottschalk R.W. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis 2007, 79(4):317-321.
20. Torok H.M., Webster G., Dunlap F.E., et al. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis 2005, 75(6):357-363.
21. Koca R., Altinyazar H.C., Ankarali H., et al. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 2009, 35(3):251-256.
22. Del Rosso J.Q., Bikowski J. Topical metronidazole combination therapy in the clinical management of rosacea. J Drugs Dermatol 2005, 4(4):473-480.
23. Del Rosso J.Q. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol 2009, 8(7):664-668.
24. Nielsen P.G. The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream [letter]. Br J Dermatol 1983, 109(1):122.
25. Dahl M.V., Katz H.I., Krueger G.G., et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998, 134(6):679-683.
26. Elewski B.E. Results of a national rosacea patient survey: common issues that concern rosacea suffers. J Drugs Dermatol 2009, 8(2):120-123.
27. Parsad D., Pandhi R., Negi K.S., et al. Topical metronidazole in seborrheic dermatitis-a double-blind study. Dermatology 2001, 202(1):35-37.
28. Koca R., Altinyazar H.C., Esturk E. Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol 2003, 42(8):632-635.
29. Siadat A.H., Iraji F., Shahmoradi Z., et al. The efficacy of 1% metronidazole gel in facial seborrheic dermatitis: a double-blind study. Indian J Dermatol Venereol Leprol 2006, 72(4):266-269.
30. Ozcan H., Seyhan M., Yologlu S. Is metronidazole 0.75% gel effective in the treatment of seborrheic dermatitis? A double-blind, placebo controlled study. Eur J Dermatol 2007, 17(4):313-316.
31. Seckin D., Gurbuz O., Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol 2007, 21(3):345-350.
32. Cicek D., Kandi B., Bakar S., et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrheic dermatitis: a randomized clinical study. J Dermatolog Treat 2009, 20(2):1-6.
33. Laude T.A., Salvemini J.N. Perioral dermatitis in children. Semin Cutan Med Surg 1999, 18(3):206-209.
34. Manders S.M., Lucky A.W. Perioral dermatitis in childhood. J Am Acad Dermatol 1992, 27(5 Pt 1):688-692.
35. Miller S.R., Shalita A.R. Topical metronidazole gel (0.75%) for the treatment of perioral dermatitis in children. J Am Acad Dermatol 1994, 31():847-848.
36. Boeck K., Abeck D., Werfel S., et al. Perioral dermatitis in children-clinical presentation, pathogenesis-related factors and response to topical metronidazole. Dermatology 1997, 195(3):235-238.
37. Nguyen V., Eichenfield L.F. Periorificial dermatitis in children and adolescents. J Am Acad Dermatol 2006, 55(5):781-785.
38. Veien N.K., Munkvad J.M., Nielsen A.O., et al. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol 1991, 24():258-260.
39. Weber K., Thurmayr R. Critical appraisal of reports on the treatment of perioral dermatitis. Dermatology 2005, 210(4):300-307.
40. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20(18 ):1S-13S.
41. Nanney L.B., McKanna J.A., Stoscheck C.M., et al. Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol 1984, 82(2):165-169.
42. Lacouture M.E., Basti S., Patel J., et al. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGRF inhibitors. J Support Oncol 2006, 4(5):236-238.
43. Li T., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009, 4(2):107-119.
44. Lorusso P. Toward evidence-based management of the dermatologic effects of EGRF inhibitors. Oncology 2009, 23(2):186-193.
45. Boone S.L., Rademaker A., Liu D., et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007, 72(3-4):152-159.
46. Lynch T.J., Kim E.S., Eaby B., et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007, 12(5):610-621.
47. Jatoi A., Rowland K., Sloan J.A., et al. Does tetracycline prevent/palliate epidermal growth factor receptor (EGRF) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB) (abstract LBA9006). J Clin Oncol 2007, 25(18S):494s.
48. Scope A., Agero A.L., Dusza S.W., et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25(34):5390-5396.
49. Agero A.L., Dusza S.W., Benvenuto-Andrade C., et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006, 55(4):657-670.
50. Scope A., Lieb J.A., Dusza S.W., et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption. J Am Acad Dermatol 2009, 61(4):614-620.
51. Segaert S., Van Cutsem E. Clinical management of EGRFI dermatologic toxicities: the European perspective. Oncology 2007, 21(11 5):22-26.
52. Galimont-Collen A.F., Vos L.E., Lavrijsen A.P. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007, 43(5):845-851.
53. Sapico F.L., Ginunas V.J., Thornhill-Joynes M., et al. Quantitative microbiology of pressure sores in different stages of healing. Diagn Microbiol Infect Dis 1986, 5(1):31-38.
54. Jones P.H., Willis A.T., Ferguson I.R. Treatment of anaerobically infected pressure sores with topical metronidazole. Lancet 1978, 1(8057):213-214.
55. Bower M., Stein R., Evans T.R., et al. A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. Eur J Cancer 1992, 28A(4-5):888-889.
56. Bale S., Tebbie N., Price P. A topical metronidazole gel used to treat malodorous wounds. Br J Nurs 2004, 13(11):S4-11.
57. Paul J.C., Pieper B.A. Topical metronidazole for the treatment of wound odor: a review of the literature. Ostomy Wound Manage 2008, 54(3):18-27.
58. Sharma V.K., Dhar S., Gill A.N. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol 1996, 23(8):530-534.
59. Gastaminza G., Anda M., Audicana M.T., et al. Fixed-drug eruption due to metronidazole with positive topical provocation. Contact Dermatitis 2001, 44(1):36.
60. Short K.A., Fuller L.C., Salisbury J.R. Fixed drug eruption following metronidazole therapy and the use of topical provocation testing in diagnosis. Clin Exp Dermatol 2002, 27(6):464-466.
61. Vila J.B., Bernier M.A., Gutierrez J.V., et al. Fixed drug eruption caused by metronidazole. Contact Dermatitis 2002, 46(2):122.
62. Watsky K.L. Acute generalized exanthematous pustulosis induced by metronidazole: the role of patch testing. Arch Dermatol 1999, 135(1):93-94.
63. Girardi M., Duncan K.O., Tigelaar R.E., et al. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. Am J Dermatopathol 2005, 27(4):343-346.
64. Jan V., Machet L., Gironet N., et al. Acute generalized exanthematous pustulosis induced by diltiazem: value of patch testing. Dermatology 1998, 197(3):274-275.
65. Britschgi M., Steiner U.C., Schmid S., et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001, 107(11):1433-1441.
66. Mashiah J., Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol 2003, 139(9):1181-1183.